Literature DB >> 11116078

Inhibition of mast cell-dependent conversion of cultured macrophages into foam cells with antiallergic drugs.

H Ma1, P T Kovanen.   

Abstract

Degranulation of isolated, rat peritoneal mast cells in the presence of low density lipoprotein (LDL) induces cholesteryl ester accumulation in cocultured macrophages with ensuing foam cell formation. This event occurs when the macrophages phagocytose LDL particles that have been bound to the heparin proteoglycans of exocytosed granules. In an attempt to inhibit such foam cell formation pharmacologically, rat peritoneal mast cells that had been passively sensitized with anti-ovalbumin-IgE were treated with 2 mast cell-stabilizing antianaphylactic drugs, MY-1250 or disodium cromoglycate (DSCG). Both drugs were found to inhibit antigen (ovalbumin)-triggered release of histamine from the mast cells, revealing mast cell stabilization. In cocultures of rat peritoneal macrophages and passively sensitized mast cells, addition of MY-1250 before addition of the antigen resulted in parallel reductions in histamine release from mast cells, uptake of [(14)C]sucrose-LDL, and accumulation of LDL-derived cholesteryl esters in the cocultured macrophages. Similarly, when passively sensitized mast cells were stimulated with antigen in the presence of DSCG and the preconditioned media containing all substances released from the drug-treated mast cells were collected and added to macrophages cultured in LDL-containing medium, uptake and esterification of LDL cholesterol by the macrophages were inhibited. The inhibitory effects of both drugs were mast cell-specific because neither drug inhibited the ability of macrophages to take up and esterify LDL cholesterol. Analysis of heparin proteoglycan contents of the incubation media revealed that both drugs had inhibited mast cells from expelling their granule remnants. Thus, both MY-1250 and DSCG prevent mast cells from releasing the heparin proteoglycan-containing vehicles that bind LDL and carry it into macrophages. This study suggests that antiallergic pharmacological agents could be used in animal models to prevent mast cell-dependent formation of foam cells in vivo.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11116078     DOI: 10.1161/01.atv.20.12.e134

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  6 in total

Review 1.  Mast cells and metabolic syndrome.

Authors:  Jie Zhang; Guo-Ping Shi
Journal:  Biochim Biophys Acta       Date:  2010-12-23

Review 2.  Emerging role of mast cells and macrophages in cardiovascular and metabolic diseases.

Authors:  Jia-Ming Xu; Guo-Ping Shi
Journal:  Endocr Rev       Date:  2012-01-12       Impact factor: 19.871

Review 3.  Mast cell chymase and tryptase as targets for cardiovascular and metabolic diseases.

Authors:  Aina He; Guo-Ping Shi
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

4.  A new class of human mast cell and peripheral blood basophil stabilizers that differentially control allergic mediator release.

Authors:  Sarah K Norton; Anthony Dellinger; Zhiguo Zhou; Robert Lenk; Darren Macfarland; Becky Vonakis; Daniel Conrad; Christopher L Kepley
Journal:  Clin Transl Sci       Date:  2010-08       Impact factor: 4.689

5.  Oxidized low-density lipoprotein contributes to atherogenesis via co-activation of macrophages and mast cells.

Authors:  Chong Chen; Damir B Khismatullin
Journal:  PLoS One       Date:  2015-03-26       Impact factor: 3.240

6.  Is atopic sensitization associated with indicators of early vascular ageing in adolescents?

Authors:  Karsten Königstein; Denis Infanger; Randi Jacobsen Bertelsen; Ane Johannessen; Ulrike Waje-Andreassen; Arno Schmidt-Trucksäss; Cecilie Svanes; Julia Dratva
Journal:  PLoS One       Date:  2019-08-15       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.